CAS: 2024548-03-4

Lin28-let-7a antagonist 1 is a small molecule inhibitor, which is a chemically synthesized compound with significant therapeutic potential. It acts by targeting the Lin28/let-7 axis, a critical regulatory pathway involved in cellular processes such as development, metabolism, and tumorigenesis. The source of this antagonist is a synthetic, rationally designed compound, optimized for high specificity and potency. The mode of action of Lin28-let-7a antagonist 1 involves the disruption of the interaction between the Lin28 protein and let-7 microRNA. Lin28 is known to bind to the precursors of the let-7 family of microRNAs, inhibiting their maturation and function. By antagonizing this interaction, the compound enables the reactivation of let-7 microRNAs, which are important tumor suppressors, thus promoting anti-proliferative and pro-differentiation effects. The primary uses and applications of Lin28-let-7a antagonist 1 are within the field of cancer research. It offers a novel approach for studying the mechanisms of malignant transformation and tumor progression, particularly in cancers where the Lin28/let-7 pathway is dysregulated. Scientists can utilize this antagonist to explore new therapeutic strategies aimed at restoring normal microRNA function in cancer cells.

Lin28-let-7a antagonist 1, with an IC50 of 4.03 μM for Lin28A-let-7a-1 interaction,and shows a clear antagonistic effect against the Lin28-let-7a interaction.

4-(7-(4-((Benzyloxy)carbonyl)piperazin-1-yl)-4,4-dimethyl-8-nitrochromeno[4,3-c]pyrazol-1(4H)-yl)benzoic acid

Lin28-let-7a antagonist 1